Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2. - Wikidata - wikimedia - TriplyDB

Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2.

Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2.

http://www.wikidata.org/entity/Q40905189

about

Identification of drug-specific pathways based on gene expression data: application to drug induced lung injury.Following the path of CCL2 from prostaglandins to periostin in lung fibrosis Nanotechnology approaches for inhalation treatment of fibrosis.Biodegradable Janus nanoparticles for local pulmonary delivery of hydrophilic and hydrophobic molecules to the lungs.Pulmonary delivery of docosahexaenoic acid mitigates bleomycin-induced pulmonary fibrosis Normal Human Lung Epithelial Cells Inhibit Transforming Growth Factor-β Induced Myofibroblast Differentiation via Prostaglandin E2 Microvascular targets for anti-fibrotic therapeutics Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention.Current and future direction in the management of scleroderma.Combinatorial treatment of idiopathic pulmonary fibrosis using nanoparticles with prostaglandin E and siRNA(s).Regulation of inflammation by lipid mediators in oral diseases.Inflammatory monocyte/macrophage modulation by liposome-entrapped spironolactone ameliorates acute lung injury in mice Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease.Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease.P311, Friend, or Foe of Tissue Fibrosis?

P2860

Q30941816-2C71162E-865D-41A5-81C7-B207111820C5 Q33799756-ADD072E2-F97F-450C-BF90-51E9628FC35F Q34449624-4E572720-8A45-4856-8B8E-FB87E4C1952B Q34464430-5B30B7A5-6B04-4F43-B7A6-C423737EB8D1 Q35151307-AF10444F-3AD9-4B2F-A506-93B207BAD891 Q35738996-201C39BD-AF67-40CA-A807-205AF4008818 Q37358577-26E3486D-5320-4DB9-9947-49C41C1709CD Q37672440-5827E67E-7D12-480F-AC95-2CD757A9489A Q38823948-0C4841B8-F923-4749-8D4A-FED521E8F57B Q38824212-9F86C77F-86D6-44EC-93EA-632E735A608E Q38899898-C40D53BE-66A5-4E60-964F-B8EF2FBB1F12 Q39739187-67B0B69E-F9C1-49C3-88D5-D1641ACE5BF0 Q47913152-90BAC48B-39FF-44D5-8F4F-F106C93D2669 Q55332823-C293D031-E5BB-474D-B811-BE30FCB76E66 Q58122659-58F5CAE8-411A-4376-BB12-AF195B7DA02B

P2860

Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2.

http://www.wikidata.org/entity/Q40905189

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2.

@en

type

label

Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2.

@en

prefLabel

Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2.

@en

P1433

Q40905189-D62A60CA-75CC-4936-8E0D-26E04DFB8144

P1476

Q40905189-93070C6F-EA58-4C59-8803-125791E80274

P2093

Q40905189-21EBE3E5-E892-46D4-A871-A48D715B61E1

Q40905189-688979A4-F304-4C8D-851D-F87497AAA442

Q40905189-706F1860-9E20-47D5-B72D-6FB654955A2B

Q40905189-982A20A7-747A-485B-8884-3CB86B296204

Q40905189-FA7782EF-BF8E-4D77-BA28-1A3E40BA2FF9

P2860

Q40905189-043D141B-3CA0-430D-A1BC-8F1200F360B9

Q40905189-0598874A-51D0-4617-8228-81F36C8D0E3E

Q40905189-06C917B8-A88A-483B-B88F-72D1FF4716B8

Q40905189-09353BC0-2C66-436F-BC50-FB33183BD817

Q40905189-2045A33C-5A75-4539-BCAB-DD144021F898

Q40905189-262F3241-6741-448B-BD94-C2E231A9F678

Q40905189-2A871041-F2D7-404B-858A-912B489DEBCF

Q40905189-3143498E-91AF-40CF-A3B3-86FFBCE5BDE8

Q40905189-38C8F533-25DC-4B03-AB6F-511059198589

Q40905189-3DAAB9EE-6D6F-4051-A24B-165EE8ABEF08

P304

Q40905189-6B30BB14-1DB1-4210-AE86-6BD5CF8C8CD1

P31

Q40905189-E91F60C6-AE26-49E7-8456-5F55D4030322

P356

Q40905189-6233903B-B763-417B-919C-DBD211FAE014

P407

Q40905189-127B47BC-A1DB-4905-9A01-6AB62ED2588C

P433

Q40905189-7DD01A7C-9DD0-49AA-8DB5-B3880179EA04

P478

Q40905189-18B74BFF-3C58-47BD-8C3D-DCD7D7B61B19

P50

Q40905189-31FF10BB-D731-4B29-A1A0-29CDC4E2CFC2

P577

Q40905189-C6C7578F-C344-43A0-9EEB-A6037E18EDD0

P698

Q40905189-A1F2642B-74E7-457C-937C-86F688FF27E5

P921

Q40905189-94E27BAB-E280-4514-B414-ACA766260CE3

P932

Q40905189-65536056-C8EE-4F78-9619-8F87F75ADD43

P356

J.EJPB.2012.11.023

P1433

European Journal of Pharmaceutics and Biopharmaceutics

P1476

Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2.

@en

P2093

David C Reimer

http://www.w3.org/2001/XMLSchema#string

Kenneth R Reuhl

http://www.w3.org/2001/XMLSchema#string

Olga B Garbuzenko

http://www.w3.org/2001/XMLSchema#string

Vera Ivanova

http://www.w3.org/2001/XMLSchema#string

Vitaly P Pozharov

http://www.w3.org/2001/XMLSchema#string

P2860

Soluble TNF mediates the transition from pulmonary inflammation to fibrosis

Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy

American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Soci

IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis

Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family

HIF-1α signaling by airway epithelial cell K-α1-tubulin: role in fibrosis and chronic rejection of human lung allografts

Endothelial-to-mesenchymal transition contributes to cardiac fibrosis

Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance.

Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment.

Characterization of lung stem cell niches in a mouse model of bleomycin-induced fibrosis.

P304

335-344

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EJPB.2012.11.023

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

84

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23228437

http://www.w3.org/2001/XMLSchema#string

P921

pulmonary fibrosis

P932

3660419

http://www.w3.org/2001/XMLSchema#string